Skip to main content
INOVIQ LTD logo

INOVIQ LTD — Investor Relations & Filings

Ticker · IIQ ISIN · AU0000196149 ASX Professional, scientific and technical activities
Open in API
Filings indexed 858 across all filing types
Latest filing 2018-11-06 Regulatory Filings
Country AU Australia
Listing ASX IIQ

About INOVIQ LTD

https://www.inoviq.com

INOVIQ LTD specializes in the development and commercialization of next-generation exosome and precision diagnostics. The company focuses on innovative solutions for the early detection and monitoring of cancer and other diseases. Its proprietary technology portfolio includes EXO-NET, a high-throughput exosome capture tool designed for research and clinical applications, and the SubB2M platform, which utilizes an engineered protein to detect the pan-cancer biomarker Neu5Gc. The company also provides the hTERT test for bladder cancer monitoring. These technologies facilitate non-invasive liquid biopsy tests aimed at improving patient outcomes through high sensitivity and specificity. The core business activities encompass the creation of diagnostic tools and research reagents for the global healthcare and life sciences sectors, emphasizing precision medicine and early intervention.

Recent filings

Filing Released Lang Actions
Pause In Trading 1 page 112.5KB
Regulatory Filings Classification · 95% confidence The document is a brief market release announcing a temporary pause in trading of the company's securities. It is very short (343 characters) and does not contain any financial data, report content, or detailed information. It is an announcement related to trading status, not a financial report or detailed filing. This fits best under Regulatory Filings (RNS), which covers general regulatory announcements and compliance notices that do not fit other categories.
2018-11-06 English
Trading Halt 2 pages 86.1KB
Regulatory Filings Classification · 95% confidence The document is a market announcement from BARD1 Life Sciences Limited regarding a trading halt requested pursuant to ASX Listing Rule 17.1. The text explicitly states that the trading halt is requested pending the release of an announcement related to a capital raising. There is no financial data, report, or detailed analysis included in the document. The document is short (2398 characters) and serves as an official notice to the market about the trading halt, not the capital raising announcement itself. Therefore, it is an announcement related to capital/financing activities but specifically a trading halt notice. According to the filing definitions, updates on company fundraising or capital structure changes fall under Capital/Financing Update (CAP). However, since this document is only about the trading halt pending such an announcement and does not contain the actual capital raising details, it is best classified as a Regulatory Filing (RNS) because it is a regulatory announcement that does not fit other categories more precisely. The document is not a full capital raising update but a procedural notice. Hence, the most appropriate classification is Regulatory Filings (RNS).
2018-11-06 English
Quarterly Activities Report and Cashflow 8 pages 350.4KB
Interim / Quarterly Report Classification · 100% confidence The document is titled 'QUARTERLY BUSINESS UPDATE' and includes detailed financial data such as cash position, net operating cash outflow, and consolidated statement of cash flows for the quarter ended 30 September 2018. It also contains substantive financial data and analysis related to the company's operations and R&D activities during the quarter. The presence of an Appendix 4C quarterly report, which is a regulatory requirement for quarterly reporting in Australia, further supports that this is a comprehensive quarterly financial report. The document is approximately 15,000 characters long, indicating it is a full report rather than a brief announcement. Therefore, this document fits the definition of an Interim / Quarterly Report (IR). Q1 2018
2018-10-30 English
Ceasing to be a substantial holder 2 pages 136.3KB
Regulatory Filings
2018-10-30 English
Notice of Annual General Meeting/Proxy Form 19 pages 595.3KB
AGM Information Classification · 100% confidence The document is titled 'NOTICE OF ANNUAL GENERAL MEETING' for BARD1 Life Sciences Limited, detailing the date, location, and agenda of the AGM. It includes instructions on voting, proxy appointments, and the agenda items such as discussion of the Annual Report for the financial year ended 30 June 2018, adoption of the Remuneration Report, re-election of a director, and approval of share placement resolutions. The document is a notice and explanatory statement for the AGM, not the Annual Report itself. It references the Annual Report and Remuneration Report but does not contain the full reports or financial statements. The document is about the meeting logistics and resolutions to be voted on, consistent with an AGM Information filing.
2018-10-29 English
Change in substantial holding 2 pages 120.2KB
Regulatory Filings
2018-10-28 English

Browse filings by year

24 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.